Source BioScience

Executive Summary

Source BioScience is a UK-based provider of specialized laboratory services, operating through two divisions: Source LDPath (histopathology/digital pathology) and Source Genomics (genomics and proteomics). The company serves biotechnology, pharmaceutical, healthcare, and academic clients, offering molecular diagnostics, Sanger sequencing, next-generation sequencing (NGS), and advanced proteomic analysis. With ISO-accredited laboratories and a focus on data quality and rapid turnaround, it has established itself as an industry-leading service partner. The company benefits from growing demand for outsourcing in drug development and diagnostics, supported by trends like precision medicine and biomarker discovery. While privately held with no disclosed financials, its long-standing presence since 1996 and broad service portfolio suggest a stable revenue base and potential for incremental growth.

Upcoming Catalysts (preview)

• Q3 2026Expansion of NGS and proteomics service capabilities70% success
• Q4 2026Partnership or contract win with major pharma/biotech50% success
• Q1 2027Adoption of AI/digital pathology in histopathology division60% success